Erratum to 'Germline-focussed analysis of tumour-only sequencing: recommendations from the ESMO Precision Medicine Working Group': [Annals of Oncology 30 (2019) 1221-1231]

D Mandelker¹, M Donoghue², S Talukdar³, C Bandlamudi², P Srinivasan², M Vivek⁴, S Jezdic⁵, H Hanson³, K Snape³, A Kulkarni⁶, L Hawkes⁷, J-Y Douillard⁵, S E Wallace⁸, E Rial-Sebbag⁹, F Meric-Bersntam¹⁰, A George¹¹, D Chubb¹², C Loveday¹², M Ladanyi¹³, M F Berger¹⁴, B S Taylor¹⁵, C Turnbull¹⁶

Affiliations

¹ Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, USA. Electronic address: mandelkd@mskcc.org.
² Marie-Josee and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, USA.
³ Department of Clinical Genetics, St George's University of London, London, UK.
⁴ Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, USA; Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, USA.
⁵ European Society for Medical Oncology (ESMO) Head Office, Lugano, Switzerland.
⁶ Department ofClinical Genetics, Guy and St Thomas' NHS Foundation Trust, London, UK.
⁷ Department of Clinical Genetics, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
⁸ Department of Health Sciences, University of Leicester, Leicester, UK.
⁹ University of Toulouse, Toulouse, France.
¹⁰ Department of Investigational CancerTherapeutics, The University of Texas MD Anderson Cancer Center, Houston, USA.
¹¹ Cancer Genetics Unit, The Royal Marsden NHS Foundation Trust, London, UK; Division of Genetics and Epidemiology, Institute of Cancer Research, London, UK.
¹² Division of Genetics and Epidemiology, Institute of Cancer Research, London, UK.
¹³ Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, USA; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, USA.
¹⁴ Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, USA; Marie-Josee and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, USA.
¹⁵ Marie-Josee and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, USA; Department of Clinical Genetics, St George's University of London, London, UK; Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, USA.
¹⁶ Department ofClinical Genetics, Guy and St Thomas' NHS Foundation Trust, London, UK; Division of Genetics and Epidemiology, Institute of Cancer Research, London, UK; William Harvey Research Institute, Queen Mary University of London, London, UK; Public Health England, London, UK. Electronic address: clare.turnbull@icr.ac.uk.

PMID: 34090768
PMCID: PMC8929238
DOI: 10.1016/j.annonc.2021.05.798

Published Erratum

Erratum to 'Germline-focussed analysis of tumour-only sequencing: recommendations from the ESMO Precision Medicine Working Group': [Annals of Oncology 30 (2019) 1221-1231]

D Mandelker et al. Ann Oncol. 2021 Aug.

. 2021 Aug;32(8):1069-1071.

doi: 10.1016/j.annonc.2021.05.798. Epub 2021 Jun 2.

Authors

Affiliations

¹ Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, USA. Electronic address: mandelkd@mskcc.org.
² Marie-Josee and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, USA.
³ Department of Clinical Genetics, St George's University of London, London, UK.
⁴ Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, USA; Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, USA.
⁵ European Society for Medical Oncology (ESMO) Head Office, Lugano, Switzerland.
⁶ Department ofClinical Genetics, Guy and St Thomas' NHS Foundation Trust, London, UK.
⁷ Department of Clinical Genetics, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
⁸ Department of Health Sciences, University of Leicester, Leicester, UK.
⁹ University of Toulouse, Toulouse, France.
¹⁰ Department of Investigational CancerTherapeutics, The University of Texas MD Anderson Cancer Center, Houston, USA.
¹¹ Cancer Genetics Unit, The Royal Marsden NHS Foundation Trust, London, UK; Division of Genetics and Epidemiology, Institute of Cancer Research, London, UK.
¹² Division of Genetics and Epidemiology, Institute of Cancer Research, London, UK.
¹³ Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, USA; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, USA.
¹⁴ Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, USA; Marie-Josee and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, USA.
¹⁵ Marie-Josee and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, USA; Department of Clinical Genetics, St George's University of London, London, UK; Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, USA.
¹⁶ Department ofClinical Genetics, Guy and St Thomas' NHS Foundation Trust, London, UK; Division of Genetics and Epidemiology, Institute of Cancer Research, London, UK; William Harvey Research Institute, Queen Mary University of London, London, UK; Public Health England, London, UK. Electronic address: clare.turnbull@icr.ac.uk.

PMID: 34090768
PMCID: PMC8929238
DOI: 10.1016/j.annonc.2021.05.798

No abstract available

PubMed Disclaimer

Figures

**Figure 1**
Distribution of variant allele frequency observed in the tumour for variants of true germline origin which were (i) small insertion/deletions (ii) SNVs.

**Figure 2**
Distribution of germline and somatic pathogenic variants detected upon tumour analysis. Only variants classified pathogenic/likely pathogenic AND above VAF threshold are included (blue, germline origin; red, somatic origin; numbers, total number of pathogenic variants. observed in tumour).

**Figure 3**
Distribution of germline and somatic pathogenic variants detected upon tumour analysis for 30 high-actionability CSGs. (A) Offtumour and (B) on-tumour.

See this image and copyright information in PMC

Erratum for

Germline-focussed analysis of tumour-only sequencing: recommendations from the ESMO Precision Medicine Working Group.
Mandelker D, Donoghue M, Talukdar S, Bandlamudi C, Srinivasan P, Vivek M, Jezdic S, Hanson H, Snape K, Kulkarni A, Hawkes L, Douillard JY, Wallace SE, Rial-Sebbag E, Meric-Bersntam F, George A, Chubb D, Loveday C, Ladanyi M, Berger MF, Taylor BS, Turnbull C. Mandelker D, et al. Ann Oncol. 2019 Aug 1;30(8):1221-1231. doi: 10.1093/annonc/mdz136. Ann Oncol. 2019. PMID: 31050713 Free PMC article.

Publication types

Actions

Grants and funding

27223/CRUK_/Cancer Research UK/United Kingdom

LinkOut - more resources

Full Text Sources

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Erratum to 'Germline-focussed analysis of tumour-only sequencing: recommendations from the ESMO Precision Medicine Working Group': [Annals of Oncology 30 (2019) 1221-1231]

Affiliations

Erratum to 'Germline-focussed analysis of tumour-only sequencing: recommendations from the ESMO Precision Medicine Working Group': [Annals of Oncology 30 (2019) 1221-1231]

Authors

Affiliations

Figures

Erratum for

Publication types

Grants and funding

LinkOut - more resources

Full Text Sources